Apricus Biosciences, Inc.
16.08.2012 15:12
---------------------------------------------------------------------------
SAN DIEGO, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
('Apricus Bio') (Nasdaq:APRI) (www.apricusbio.com) today announced a podium
presentation titled, 'Updated analyses of a randomized, double-blind, Phase 3
study of Femprox(r), an alprostadil cream with a novel transdermal delivery
technology (NexACT(r)) for the treatment of female sexual arousal disorder
(FSAD),' will take place on Monday, August 27, 2012, at 4:30 p.m. CT, as part
of the 2012 World Meeting on Sexual Medicine, which is being held August 26-30,
2012 in Chicago.
The presentation will discuss an updated analysis of the approximately
400-women Phase III clinical trial conducted by Apricus Bio to provide further
evidence of the statistically significant efficacy and safety profile of
Apricus Bio's investigational drug, Femprox(r) (topical alprostadil 0.4 %
cream),
for the treatment of FSAD in pre- and post-menopausal women.
The data will be presented by Dr. Irwin Goldstein, Director of Sexual Medicine
at the Alvarado Hospital in San Diego, and a member of Apricus Bio's Femprox(r)
Clinical Advisory Board. Dr. Goldstein is the Editor of The Journal of Sexual
Medicine, a member of numerous sexual medicine societies, the author or
co-author of approximately 260 peer-reviewed papers, and an expert in the area
of women's sexual health.
About Femprox(r)
Femprox(r) is an alprostadil-based 0.4% topical cream intended for the treatment
of FSAD. Apricus Bio has completed nine clinical studies to date, including
one, 98-patient Phase II study in the U.S. and a near 400-patient Phase III
study in China.
It is the Company's understanding that no product is currently approved in the
U.S. for FSAD, a persistent or recurring inability to attain, or maintain
adequate sexual excitement, causing personal distress.
Femprox(r) exerts a local, relaxant effect on vulvar and clitoral blood vessels
in women, leading to increased blood flow. The resultant increase in
lubrication and sensory feedback is believed to produce a clinically
significant increase in sexual arousal in women with FSAD.
About Apricus Biosciences, Inc.
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
high-demand therapeutic classes. The Company has four approved products and has
developed a strong pipeline of multiple late-stage product opportunities. With
commercial operations in both the U.S. and Europe (France), Apricus Bio
generates revenues and growth from sales of its commercial products and by
out-licensing, in certain territories, its pipeline products and NexACT(r)
technology.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Abbot Laboratories, Sandoz, Warner Chilcott, Wockhardt, and Bracco, and
co-promotes multiple products in France.
Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on
the NASDAQ under the ticker symbol APRI.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its products and product candidates such as
Femprox(r) receive patent protection and be approved by relevant regulatory
authorities, to successfully commercialize such products and product candidates
as Femprox(r) and drug delivery technology and to achieve its development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
16.08.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences Announces Podium Presentation of Femprox(R) Phase III Clinical Data at 2012 World Meeting on Sexual Medicine
| Source: EQS Group AG